CA Patent

CA2470519C — Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5

Assigned to Merck and Co Inc · Expires 2009-11-17 · 16y expired

What this patent protects

Pyrrole compounds selected from the group consisting of 3-(1-pyridin-2-yl-1H-pyrrol-3-yl)benzonitrile; 2-[3-(3-chlorophenyl)-1H-pyrrol-1-yl]pyridine; 2-[3-(3-methoxyphenyl)-1H-pyrrol-1-yl]pyridine; 3-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 2-{1-[3-(trifluoromethyl)phenyl]-1H…

USPTO Abstract

Pyrrole compounds selected from the group consisting of 3-(1-pyridin-2-yl-1H-pyrrol-3-yl)benzonitrile; 2-[3-(3-chlorophenyl)-1H-pyrrol-1-yl]pyridine; 2-[3-(3-methoxyphenyl)-1H-pyrrol-1-yl]pyridine; 3-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 2-{1-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}pyridine; 2-[1-(3,5-dichlorophenyl)-1H-pyrrol-3-yl]pyridine; 2-[1-(3-methylphenyl)-1H-pyrrol-3-yl]pyridine; 2-[1-(3-methoxyphenyl)-1H-pyrrol-3-yl]pyridine; 3-[3-(1,3-thiazol-2-yl)-1H-pyrrol-1-yl]benzonitrile; 3-fluoro-5-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 3-(3-bromo-4-pyridin-2-yl-1H-pyrrol-1-yl)-5-fluorobenzonitrile; 3-fluoro-5-(3-methyl-4-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 3-(3-chloro-4-pyridin-2-yl-1H-pyrrol-1-yl)-5-fluorobenzonitrile; 3-fluoro-5-[3-(1H-pyrazol-1-yl)-1H-pyrrol-1-yl]benzonitrile; 2-chloro-6-(3-pyridin-2-yl-1H-pyrrol-1-yl)pyridine; 2-(pyridin-3-yloxy)-6-(3-pyridin-2-yl-1H-pyrrol-1-yl)pyridine; 2-chloro-4-methyl-6-(3-pyridin-2-yl-1H-pyrrol-1-yl)pyridine; 3-chloro-5-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 2-{1-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-1H-pyrrol-3-yl} pyridine; 3-bromo-5-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 3-methyl-5-(3-pyridin-2-yl-1H-pyrrol-1-yl)benzonitrile; 3-fluoro-5-[3-(1,3-thiazol-2-yl)-1H-pyrrol-1-yl]benzonitrile; and pharmaceuticallyacceptable salts thereof, are characterized by being substituted directly with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, and are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.

Drugs covered by this patent

Patent Metadata

Patent number
CA2470519C
Jurisdiction
CA
Classification
Expires
2009-11-17
Drug substance claim
No
Drug product claim
No
Assignee
Merck and Co Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.